	US 12,257,294 B2
	Therapeutics for autoimmune disease: synthetic antigens
Kira Astakhova, Copenhagen SV (DK)
Assigned to DANMARKS TEKNISKE UNIVERSITET, Kongens Lyngby (DK)
Appl. No. 16/966,184
Filed by DANMARKS TEKNISKE UNIVERSITET, Kgs. Lyngby (DK)
PCT Filed Feb. 4, 2019, PCT No. PCT/EP2019/052677 § 371(c)(1), (2) Date Jul. 30, 2020, PCT Pub. No. WO2019/149946, PCT Pub. Date Aug. 8, 2019.
Claims priority of application No. 18154924 (EP), filed on Feb. 2, 2018.
Prior Publication US 2022/0193210 A1, Jun. 23, 2022
Int. Cl. A61K 39/00 (2006.01); A61K 9/51 (2006.01); A61K 31/728 (2006.01); A61K 47/36 (2006.01); A61K 47/60 (2017.01); A61P 37/06 (2006.01); A61K 47/69 (2017.01)

CPC A61K 39/0008 (2013.01) [A61K 9/5161 (2013.01); A61K 31/728 (2013.01); A61K 47/36 (2013.01); A61K 47/60 (2017.08); A61P 37/06 (2018.01); A61K 2039/6018 (2013.01); A61K 2039/6087 (2013.01); A61K 2039/627 (2013.01); A61K 47/6939 (2017.08)]

6 Claims

1. A nanoconjugate complex comprising: i) at least one autoantigen, wherein the autoantigen comprises SEQ ID NO:10, ii) a nanocarrier, wherein the nanocarrier is chitosan, and iii) at least one helper moiety, wherein the helper moiety is hyaluronic acid.